Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases;Uso de inmunoglobulina humana endovenosa en pacientes con necrolisis epidérmica tóxica y síndrome de sobreposición Stevens Johnson necrolisis tóxica epidérmica

Revista Medica de Chile

Volumn 137, Issue 3, 2009, Pages 383-389

  Molgó, Montserrat ^a   Carreño, Néstor ^a   Hoyos Bachiloglu, Rodrigo ^b   Andresen, Max ^a   González, Sergio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Epidermal necrolysis; Immunoglobulins; Stevens Johnson syndrome; Toxic

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHILE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHILE; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; SURVIVAL RATE;

EID: 67651161976     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
2. Becker DS. Toxic epidermal necrolysis. Lancet 1998; 351: 1417-20.
3. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5.
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
5. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
6. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
7. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multi-center retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
8. Bachot N, Revuz J, Roujeau JC. Intravenous immuno-globulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non-comparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
9. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-52.
10. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112(6 Pt 1): 1430-6.
11. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83: 430-2.
12. Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005; 85: 497-502.
13. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci 2005; 329: 95-8.
14. Shortt R, Gómez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-55.
15. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-8.
16. Andresen M, Boghero Y, Molgó M, Dougnac A, Díaz O. Necrolisis epidérmica tóxica. Terapia en UCI con inmunoglobulinas intravenosas en un caso. Rev Méd Chile 2000; 128: 1343-8.
17. Roujeau JC. Medication use and the risk of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis. N Engl J Med 1995; 333: 1600-7.
18. Molgó M, Palisson F. Necrólisis epidérmica tóxica. Rev Chilena Dermatol 1998; 14.
19. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30: 600-2.
20. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669-76.
21. Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, Gao YY et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005; 112: 904-12.